← Back
Data updated: Nov 8, 2026
NODEN PHARMA
Specialty Pharmaceuticals
NODEN PHARMA is a specialty pharmaceutical company with 2 FDA-approved products.
2008
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
NODEN PHARMA's Key Drugs
NODEN PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
NODEN PHARMA's Recent FDA Approvals
New NDA/BLA approvals for NODEN PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
NODEN PHARMA's Therapeutic Areas
Disease areas where NODEN PHARMA has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
NODEN PHARMA Pipeline Snapshot
Active clinical trials for NODEN PHARMA across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2008-01-18
- Latest
- 2020-09-28
- Applications
- 2